4/A: Processa Pharmaceuticals CEO George Ng Amends Filing to Clarify Beneficial Ownership of Shares and Warrants
SEC Form 4/A (Amendment)
George Ng, CEO of Processa Pharmaceuticals, files an amendment to a previous Form 4, clarifying the beneficial ownership of common stock and warrants held indirectly through a trust and an IRA.
Summary
- George Ng, the CEO of Processa Pharmaceuticals, filed an amended Form 4 with the SEC.
- The amendment clarifies the beneficial ownership of Processa Pharmaceuticals securities.
- Ng indirectly owns 87,200 shares of common stock through George Ng IRRA FBO: George Ng.
- He also indirectly owns 20,000 shares through the Ng Cha Family Trust.
- The filing also reports the acquisition of 87,200 warrants with an exercise price of $0.65, expiring on 01/29/2030, held indirectly through George Ng IRRA FBO: George Ng.
- Additionally, 43,600 warrants with the same terms are held indirectly through George Ng IRRA FBO: George Ng.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral. It simply reports changes in beneficial ownership.
Industry Context
Form 4 filings are standard practice for company insiders to report changes in their beneficial ownership of company securities, ensuring transparency and compliance with SEC regulations.
Comparison to Industry Standards
- Comparing George Ng's holdings to other pharmaceutical CEOs is difficult without knowing the specific details of their compensation packages and investment strategies.
- However, it's common for CEOs to hold a mix of stock options, restricted stock, and shares acquired through open market purchases.
- The size of their holdings often reflects their tenure, performance, and the overall size and stage of the company.
- For example, the CEO of a large, established pharmaceutical company like Pfizer or Johnson & Johnson would likely have significantly larger holdings than the CEO of a smaller, development-stage company like Processa Pharmaceuticals.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the CEO's stake in the company.
- It assures stakeholders that the CEO's interests are aligned with theirs.
Key Dates
| Date | Description |
|---|---|
| 01/27/2025 | Date of earliest transaction |
| 01/29/2025 | Original filing date and transaction date for warrants |
| 01/29/2025 | Warrants become exercisable |
| 01/29/2030 | Expiration date for warrants |
| 02/18/2025 | Date of signature for the amended filing |
Keywords
Form 4, Beneficial Ownership, SEC Filing, Processa Pharmaceuticals, George Ng, Warrants, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.